Toshio Kubo

3.8k total citations
128 papers, 2.1k citations indexed

About

Toshio Kubo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Toshio Kubo has authored 128 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Pulmonary and Respiratory Medicine, 82 papers in Oncology and 23 papers in Surgery. Recurrent topics in Toshio Kubo's work include Lung Cancer Treatments and Mutations (67 papers), Lung Cancer Research Studies (33 papers) and Colorectal Cancer Treatments and Studies (20 papers). Toshio Kubo is often cited by papers focused on Lung Cancer Treatments and Mutations (67 papers), Lung Cancer Research Studies (33 papers) and Colorectal Cancer Treatments and Studies (20 papers). Toshio Kubo collaborates with scholars based in Japan, United States and South Korea. Toshio Kubo's co-authors include Hidenobu Watanabe, Katsuyuki Kiura, Eiki Ichihara, Katsuyuki Hotta, Tamaki Imai, Kadoaki Ohashi, Takashi Ninomiya, Nagio Takigawa, Mitsune Tanimoto and Masahiro Tabata and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Toshio Kubo

119 papers receiving 2.0k citations

Peers

Countries citing papers authored by Toshio Kubo

Since Specialization

Citations

This map shows the geographic impact of Toshio Kubo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toshio Kubo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toshio Kubo more than expected).

Fields of papers citing papers by Toshio Kubo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toshio Kubo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toshio Kubo. The network helps show where Toshio Kubo may publish in the future.

Co-authorship network of co-authors of Toshio Kubo

This figure shows the co-authorship network connecting the top 25 collaborators of Toshio Kubo. A scholar is included among the top collaborators of Toshio Kubo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toshio Kubo. Toshio Kubo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Plasma S100A8/A9 level predicts response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer 2025 ·Scientific Reports ·(unknown), Rie Kinoshita, Kiichiro Ninomiya, Go Makimoto, Toshio Kubo, Kammei Rai, Eiki Ichihara, (unknown), Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura, Shinichi Toyooka, Masakiyo Sakaguchi, Kadoaki Ohashi	0
2	Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02. 2024 ·Journal of Clinical Oncology ·Pasi A. Jänne, (unknown), Toshio Kubo, Kiichiro Ninomiya, Sang‐We Kim, David Planchard, Myung‐Ju Ahn, Egbert F. Smit, Adrianus J. de Langen, M. Pérol, Elvire Pons‐Tostivint, Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, Dong‐Wan Kim, Kaline Pereira, (unknown), Ayumi Taguchi, Yingkai Cheng, Kōichi Goto	4
3	510MO Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer (mNSCLC): Subgroup analysis of DESTINY–Lung02 (DL-02) 2023 ·Annals of Oncology ·Yasushi Goto, Kōichi Goto, Toshio Kubo, Kiichiro Ninomiya, S-W. Kim, M-J. Ahn, Kazuhiko Nakagawa, Hidetoshi Hayashi, Junichi Shimizu, Dongwook Kim, (unknown), (unknown), K.H. Lee, (unknown), Kaline Pereira, Ayumi Taguchi, Ahmed Ali, (unknown), (unknown), Pasi A. Jänne	2
4	MA13.10 Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02 2023 ·Journal of Thoracic Oncology ·Pasi A. Jänne, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, (unknown), (unknown), Myung‐Ju Ahn, Egbert F. Smit, Adrianus J. de Langen, M. Pérol, (unknown), Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, D.-W. Kim, (unknown), Fang Cheng, Ayumi Taguchi, Yun Cheng, Kōichi Goto	2
5	Efficacy of immune checkpoint inhibitor monotherapy in elderly patients with non-small-cell lung cancer 2023 ·Respiratory Investigation ·Toshio Kubo, Eiki Ichihara, Daijiro Harada, Koji Inoue, Keiichi Fujiwara, (unknown), Daizo Kishino, Haruyuki Kawai, Nobuaki Ochi, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura	3
6	Effect of a Cyclooxygenase-2 Inhibitor in Combination with (-)-Epigallocatechin Gallate or Polyphenon E on Cisplatin-Induced Lung Tumorigenesis in A/J Mice. 2023 ·PubMed ·Ken Sato, Nagio Takigawa, Toshio Kubo, Hideki Katayama, Daizo Kishino, Toshiaki Okada, Akiko Hisamoto, (unknown), Nobuaki Ochi, (unknown), Hiroshi Ueoka, Mitsune Tanimoto, (unknown), Katsuyuki Kiura	1
7	SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1- , or EGFR -altered Non–small Cell Lung Cancer 2021 ·Molecular Cancer Therapeutics ·Hirohisa Kano, Eiki Ichihara, Hiromi Watanabe, Kazuya Nishii, (unknown), (unknown), Kiichiro Ninomiya, Yuka Kato, Toshio Kubo, Kammei Rai, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura	13
8	A case of bullous pemphigoid after a long‐term administration of anti‐PD‐1 antibodies in a patient with non‐small‐cell lung cancer 2021 ·Journal of Cutaneous Immunology and Allergy ·Emi Yokoyama, Osamu Yamasaki, Toshio Kubo, Hiroshi Koga, Norito Ishii, Shin Morizane	1
9	Demand for weekend outpatient chemotherapy among patients with cancer in Japan 2020 ·Supportive Care in Cancer ·Hideki Katayama, Masahiro Tabata, Toshio Kubo, Katsuyuki Kiura, Junji Matsuoka, Yoshinobu Maeda	6
10	Clinical characteristics of Japanese candidates for lung transplant for interstitial lung disease and risk factors for early death while on the waiting list 2017 ·Respiratory Investigation ·Hisao Higo, Takeshi Kurosaki, Eiki Ichihara, Toshio Kubo, Kentaroh Miyoshi, Shinji Otani, Seiichiro Sugimoto, Masaomi Yamane, (unknown), Katsuyuki Kiura, Shinichiro Miyoshi, Takahiro Oto	12
11	A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non–Small Cell Lung Cancer 2017 ·Journal of Thoracic Oncology ·Katsuyuki Hotta, Keisuke Aoe, Toshiyuki Kozuki, Kadoaki Ohashi, Kiichiro Ninomiya, Eiki Ichihara, Toshio Kubo, Takashi Ninomiya, Kenichi Chikamori, Daijiro Harada, Naoyuki Nogami, Taizo Hirata, Shiro Hinotsu, Shinichi Toyooka, Katsuyuki Kiura	123
12	Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines. 2015 ·Europe PMC (PubMed Central) ·Hiromichi Yamane, Hideko Isozaki, Masami Takeyama, Nobuaki Ochi, Kenichiro Kudo, Yoshihiro Honda, (unknown), Toshio Kubo, Katsuyuki Kiura, Nagio Takigawa	27
13	Afatinib Prolongs Survival Compared with Gefitinib in an Epidermal Growth Factor Receptor-Driven Lung Cancer Model 2013 ·Molecular Cancer Therapeutics ·Takashi Ninomiya, Nagio Takigawa, Eiki Ichihara, Nobuaki Ochi, (unknown), Yoshihiro Honda, Toshio Kubo, Daisuke Minami, Kenichiro Kudo, Mitsune Tanimoto, Katsuyuki Kiura	54
14	JAK2‐related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor‐activating mutation 2012 ·Cancer Science ·Daijiro Harada, Nagio Takigawa, Nobuaki Ochi, Takashi Ninomiya, Masayuki Yasugi, Toshio Kubo, (unknown), Eiki Ichihara, Kadoaki Ohashi, (unknown), Mitsune Tanimoto, Katsuyuki Kiura	38
15	STAT3 expression in activating EGFR-driven adenocarcinoma of the lung 2011 ·Lung Cancer ·(unknown), Nagio Takigawa, Yoshihiko Segawa, Toshio Kubo, Kadoaki Ohashi, Toshiyuki Kozuki, Norihiro Teramoto, Motohiro Yamashita, Shinichi Toyooka, Mitsune Tanimoto, Katsuyuki Kiura	17
16	Chemopreventive Effects of Gefitinib on Nonsmoking-Related Lung Tumorigenesis in Activating Epidermal Growth Factor Receptor Transgenic Mice 2009 ·Cancer Research ·Kadoaki Ohashi, Nagio Takigawa, (unknown), Eiki Ichihara, (unknown), Toshio Kubo, Seiki Hirano, Tadashi Yoshino, Minoru Takata, Mitsune Tanimoto, Katsuyuki Kiura	17
17	Emergence of the EGFR T790M mutation in a lung adenocarcinoma cell line after vandetanib treatment 2008 ·Cancer Research ·Eiki Ichihara, Kadoaki Ohashi, Nagio Takigawa, (unknown), (unknown), Toshio Kubo, Masahiro Tabata, Mitsune Tanimoto, Katsuyuki Kiura	0
18	Analysis of fractures in patients with rheumatoid arthritis 2003 ·Kei Sakao, Daisaku Tokunaga, (unknown), (unknown), Kazuya Ikoma, Toshio Kubo	1
19	Gastric carcinoma in New Zealand 1973 ·Cancer ·Toshio Kubo	16
20	Histologic appearance of gastric carcinoma in high and low mortality countries: Comparison between Kyushu, Japan and Minnesota, U.S.A. 1971 ·Cancer ·Toshio Kubo	50

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact